Brief Article
Copyright ©2010 Baishideng Publishing Group Co.
World J Gastroenterol. Dec 14, 2010; 16(46): 5881-5888
Published online Dec 14, 2010. doi: 10.3748/wjg.v16.i46.5881
Table 1 Data about patients enrolled in this study
CharacteristicsPatients, n (%)
Sex
Male59 (65.6)
Female31 (34.4)
Age (yr)
Median53
Range23-75
Tumor site
Colon39 (43.3)
Rectal51 (56.7)
Combined chemotherapy
Irinotecan-based58 (64.4)
Oxaliplatin-based29 (32.2)
Monotherapy3 (3.3)
Cetuximab use
First line29 (32.2)
Second line23 (25.6)
Third line28 (31.1)
Fourth line or more10 (11.1)
Response status
Complete response3 (3.3)
Partial response31 (34.4)
Stable disease35 (38.9)
Progressive disease21 (23.3)
Table 2 Correlation of KRAS gene status and phosphatase and tensin protein expression with clinical response to cetuximab in previously treated colorectal cancer patients n (%)
KRAS
PTEN
MutationNo mutationPPositiveNegativeP
CR0 (0)2 (5.1)0.0012 (5.4)0 (0)0.001
PR1 (4.5)16 (41.0)16 (43.2)1 (4.2)
SD7 (31.8)17 (43.6)10 (27.0)14 (58.3)
PD14 (63.6)4 (10.3)9 (24.3)9 (37.5)
Total22 (100)39 (100)37 (100)24 (100)